An antibody-based therapy against IL1RAP efficiently targeted CML LSCs by blocking IL-1 signaling [31], while chronic exposure to IL-1 leads to exhaustion of healthy HSCs [104]. Here, IL1A is linked to chronic myelogenous leukemia, BCR-ABL1 positive.